Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 915,914
  • Shares Outstanding, K 77,423
  • Annual Sales, $ 326,550 K
  • Annual Income, $ -287,100 K
  • 60-Month Beta 1.19
  • Price/Sales 2.51
  • Price/Cash Flow N/A
  • Price/Book 65.12
Trade CHRS with:

Options Overview Details

View History
  • Implied Volatility 100.41% ( -9.50%)
  • Historical Volatility 80.00%
  • IV Percentile 89%
  • IV Rank 40.44%
  • IV High 185.24% on 07/19/22
  • IV Low 42.80% on 09/09/21
  • Put/Call Vol Ratio 0.42
  • Today's Volume 380
  • Volume Avg (30-Day) 574
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 10,244
  • Open Int (30-Day) 6,701

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.82
  • Number of Estimates 2
  • High Estimate -0.82
  • Low Estimate -0.83
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -67.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.98 +69.48%
on 07/25/22
11.91 -0.67%
on 08/05/22
+3.29 (+38.52%)
since 07/05/22
3-Month
5.60 +111.25%
on 06/16/22
11.91 -0.67%
on 08/05/22
+3.01 (+34.13%)
since 05/05/22
52-Week
5.60 +111.25%
on 06/16/22
19.32 -38.77%
on 11/16/21
-1.13 (-8.72%)
since 08/05/21

Most Recent Stories

More News
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript

CHRS earnings call for the period ending June 30, 2022.

CHRS : 11.83 (+11.81%)
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 11.83 (+11.81%)
FEMY : 2.20 (+7.84%)
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway...

CHRS : 11.83 (+11.81%)
Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know

The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

CHRS : 11.83 (+11.81%)
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales...

CHRS : 11.83 (+11.81%)
Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

CHRS : 11.83 (+11.81%)
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022...

CHRS : 11.83 (+11.81%)
Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?

Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

BIOVF : 21.2000 (-1.03%)
CHRS : 11.83 (+11.81%)
Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

CHRS : 11.83 (+11.81%)
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer...

CHRS : 11.83 (+11.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 13.75
2nd Resistance Point 12.83
1st Resistance Point 12.33
Last Price 11.83
1st Support Level 10.91
2nd Support Level 9.99
3rd Support Level 9.49

See More

52-Week High 19.32
Fibonacci 61.8% 14.08
Fibonacci 50% 12.46
Last Price 11.83
Fibonacci 38.2% 10.84
52-Week Low 5.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar